FDA Grants Priority Review for Takeda and Protagonist’s Polycythemia Vera Drug
Event summary
- The FDA accepted the NDA for rusfertide, a first-in-class hepcidin mimetic peptide therapeutic for polycythemia vera, and granted it Priority Review.
- Rusfertide has received Breakthrough Therapy, Orphan Drug, and Fast Track designations from the FDA.
- The PDUFA goal date is set in the third quarter of 2026.
- Takeda and Protagonist entered a worldwide license and collaboration agreement for rusfertide in January 2024.
The big picture
Takeda's collaboration with Protagonist on rusfertide underscores the strategic importance of addressing unmet needs in rare hematologic disorders. The FDA's Priority Review designation highlights the potential of this first-in-class therapy to improve clinical outcomes for polycythemia vera patients, a market currently dominated by older treatments like hydroxyurea and phlebotomy.
What we're watching
- Regulatory Timeline
- Whether the FDA will meet its PDUFA goal date in Q3 2026 for rusfertide's approval.
- Commercial Strategy
- How Takeda and Protagonist will navigate the co-commercialization option for rusfertide in the U.S.
- Clinical Efficacy
- The long-term durability of response and safety profile of rusfertide as indicated by ongoing studies.
Related topics